Olodanrigan
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Olodanrigan
Description:
Olodanrigan (EMA401) is a highly selective, orally active, peripherally restricted angiotensin II type 2 receptor (AT2R) antagonist. It is under development as a neuropathic pain therapeutic agent. Olodanrigan (EMA401) analgesic action appears to involve inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons[1][2][3][4].Product Name Alternative:
EMA401; PD-126055; (S) -EMA400UNSPSC:
12352005Hazard Statement:
H302, H315, H319, H335Target:
Angiotensin ReceptorType:
Reference compoundRelated Pathways:
GPCR/G ProteinApplications:
Neuroscience-NeuromodulationField of Research:
Neurological Disease; Endocrinology; Cardiovascular DiseaseAssay Protocol:
https://www.medchemexpress.com/EMA401.htmlPurity:
98.89Solubility:
DMSO : 200 mg/mL (ultrasonic) |H2O : < 0.1 mg/mLSmiles:
O=C ([C@H]1N (C (C (C2=CC=CC=C2) C3=CC=CC=C3) =O) CC4=C (C (OCC5=CC=CC=C5) =C (OC) C=C4) C1) OMolecular Formula:
C32H29NO5Molecular Weight:
507.58Precautions:
H302, H315, H319, H335References & Citations:
[1]Anand U et al. Mechanisms underlying clinical efficacy of Angiotensin II type 2 receptor (AT2R) antagonist EMA401 in neuropathic pain: clinical tissue and in vitro studies. Mol Pain. 2015 Jun 26;11:38.|[2]Suguru Koyama, et al. An Electroencephalography Bioassay for Preclinical Testing of Analgesic Efficacy.|[3]Rice AS et al. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet. 2014 May 10;383 (9929) :1637-47.Shipping Conditions:
Room TemperatureStorage Conditions:
-20°C, 3 years; 4°C, 2 years (Powder)Scientific Category:
Reference compound1Clinical Information:
Phase 2Isoform:
AT2 ReceptorCAS Number:
1316755-16-4
